Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
A little mitochondrial stress early in life could go a long way for heart health. A new Salk Institute study found that mild mitochondrial stress during embryonic development protects mice from chemotherapy-induced heart failure — and scientists have now mapped out exactly how it works, pointing to a promising new class of heart-protective therapies.
A new study from the Salk Institute reveals that a little stress can go a long way — at least for mitochondria. Published in Science Advances, the research shows that inducing mild mitochondrial stress during embryonic development in mice provides lasting protection against heart damage, even when those mice are later exposed to doxorubicin, a chemotherapy drug notorious for causing heart failure.
The team uncovered the molecular chain reaction behind this effect: mild stress triggers a buildup of superoxide (a reactive oxygen species), which disrupts energy production and causes citrate to accumulate. Citrate then exits the mitochondria and is converted into acetyl-CoA, a molecule that drives long-lasting epigenetic changes — essentially reprogramming cells to be more resilient.
Key Takeaways:
Why it matters: This research reframes how we think about mitochondrial stress and opens the door to novel therapies that could protect the heart — and potentially other organs — from age-related decline and treatment-related damage.
